“BIORIMA* activities are progressing successfully! The mid-term report on activities gives us full confidence in the project's ability to achieve the ambitious goal of providing an Integrated Risk Management framework for nano-biomaterials (NMB) used in advanced therapy medicinal products and medical devices.” Essentially, this is a summary of the General Assembly meeting which took place in Rome on November 5-6th at the CNR premises (National Council of Research, a partner in BIORIMA and the local organizer of the meeting).
All workpackages are progressing in line with timescales, including the development of tools for materials characterization, fate and exposure analysis, testing for human and environmental hazard, risk assessment and management, considering the whole life cycle of NBM: from production, to use, up to disposal.
On November 7th, immediately after the General Assembly meeting, the first BIORIMA decision support system (DSS) prototype was shown to a group of stakeholders from industry and regulatory institutions during the second “BIORIMA Stakeholder Workshop” at the premises of Università Tor Vergata (in Rome) - a partner in BIORIMA. Fruitful discussions with stakeholders confirmed that BIORIMA is committed to delivering an integrated risk management framework which is tailored to industry users and their needs, as well as being in line with regulatory demands.
The next key events and dates for the public are: the third BIORIMA training school, 2020. This will be organized together with other 6 EU-funded projects and take place during March 22-27th); and the General Assembly meeting with a public stakeholder workshop, which will take place later in the year in Venice.
Stay tuned through our website, twitter and LinkedIn! www.biorima.eu